Autonomix Medical, Inc. · NASDAQ:AMIX
Autonomix Medical — Corporate Update (June 2024)
13 slides from Autonomix Medical's corporate update, Jun 18, 2024
Slide 1: Transforming Nerve-Targeted Treatments
Nasdaq: AMIX autonomix.com AUTONOMIX Transforming Nerve-Targeted Treatments Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,”
Slide 3: Lori Bisson, Executive Vice Chairman
Lori Bisson Executive Vice Chairman Autonomix Medical, Inc. ZF AUTONOMIX
Slide 4: Testimonials from First in Human Trial to Evaluate RF Ablation to Reduce Pain Associated with Pancreatic Cancer
Testimonials from First in Human Trial to Evaluate Radiofrequency (RF) Ablation to Reduce Pain Associated with Pancreatic Cancer AUTONOMIX
Slide 5: Pain Associated with Pancreatic Cancer Remains a Major Unmet Need
Pain Associated with Pancreatic Cancer Remains a Major Unmet Need Negatively Impacting Both Quality of Life and Survival Cancer-Related Pain Pancreatic Cancer Further Often Leads to: Illustrates the Problem: Poor diet and lower caloric intake 11" most prevalent cancer worldwide Poor quantity and qua
Slide 6: Ongoing Proof-of-Concept Clinical Trial in Pain Associated with Pancreatic Cancer
Ongoing Proof-of-Concept Clinical Trial in Pain Associated with Pancreatic Cancer Study Design y Objective The primary objective is: 20 Assess successful placement of the catheter adjacentto Number of Subjects: nerves targeted for ablation The secondary objectives are: a — Device- and procedure-rela
Slide 7: Demonstrated Significant Pain Reduction at Day 7 Follow-Up
Demonstrated Significant Pain Reduction at 7 Day Follow-Up PANCREATIC CANCER PAIN PROOF-OF-CONCEPT STUDY: RESPONDERS MEAN VAS SCORE OVER TIME Screening (n=3) Pre-procedure (n=3) Post-procedure (+24 7 Days Follow-Up (+/- Hours) (n=3) 48 Hours) (n=3)
Slide 8: Meaningful Improvement in Quality of Life
Meaningful Improvement in Quality of Life PANCREATIC CANCER PAIN PROOF-OF-CONCEPT STUDY: RESPONDERS MEAN QUALITY OF LIFE SCORES +78% +45% Improvement Pen A 7 = Excellent 1=Very Poor Baseline 7 Day Follow-Up Baseline 7 Day Follow-Up Responders Mean Quality of Health Score Responders Mean Quality of L
Slide 9: Responder VAS Score: Day 7 Follow-Up
Responder VAS Score: 7 Day Follow-Up PANCREATIC CANCER PAIN PROOF-OF-CONCEPT STUDY: BY RESPONDER VAS SCORE OVER TIME Patient 1 “Since the procedure, my life has improved because I'm able to eatand do light housework. | also returned to work and have started going to parties again. | consider myself
Slide 10: Key Conclusions
Key Conclusions AUTONOMIX D ¥ 60% of subjects responded with a mean 6.33 reduction of pain on the VAS pain scale ¥ 100% of responder group had clinically meaningful pain relief at 7 days post-procedure v Pain relief was experienced as quick as 1-day post-procedure y¥ No immediate procedural-related
Slide 11: Trial Timelines
Trial Timelines: Timelines Q1 2024 Q1 2024 June 2024 Before Year 1H 2025 Secures Principal Commence Positive Preliminary End 2024 Topline Data Investigators Enrollment and Topline Results from from POC Trial Treatments First Five Lead-In Complete Enrollment Patients ZF AUTONOMIX
Slide 12: Introducing Brad Hauser, President and CEO
ZA AUTONOMIX Introducing Brad Hauser Recently Appointed President and Chief Executive Officer of Autonomix Medical, Inc. 12
Slide 13: 2
2